Is Seelos Therapeutics Inc (SEEL) Holding Up Well Over a Long-Time Horizon?

At the time of writing, Seelos Therapeutics Inc [SEEL] stock is trading at $3.90, down -22.00%. An important factor to consider is whether the stock is rising or falling in short-term value. The SEEL shares have gain 21.63% over the last week, with a monthly amount drifted -12.48%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

From an analyst’s perspective:

Seelos Therapeutics Inc [NASDAQ: SEEL] stock has seen the most recent analyst activity on September 27, 2021, when ROTH Capital upgraded its rating to a Buy and also boosted its price target to $8 from $2.50. Previously, Guggenheim started tracking the stock with Buy rating on July 01, 2021, and set its price target to $8. On June 01, 2021, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $10 on the stock. ROTH Capital downgraded its rating to a Neutral. B. Riley Securities initiated its recommendation with a Buy and recommended $15 as its price target on March 30, 2021. The Benchmark Company started tracking with a Speculative Buy rating for this stock on November 14, 2019, and assigned it a price target of $4. In a note dated May 14, 2019, ROTH Capital initiated an Buy rating.

For the past year, the stock price of Seelos Therapeutics Inc fluctuated between $2.90 and $848.64. Seelos Therapeutics Inc [NASDAQ: SEEL] shares were valued at $3.90 at the most recent close of the market.

Analyzing the SEEL fundamentals

According to Seelos Therapeutics Inc [NASDAQ:SEEL], the company’s sales were 2.00M for trailing twelve months, which represents an 33.30% jump. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -14.8%, Pretax Profit Margin comes in at 2.03%, and Net Profit Margin reading is 2.03%. To continue investigating profitability, this company’s Return on Assets is posted at 1.72, Equity is -0.13 and Total Capital is 1.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.36.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.55 points at the first support level, and at 3.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.41, and for the 2nd resistance point, it is at 4.92.

Ratios To Look Out For

It is important to note that Seelos Therapeutics Inc [NASDAQ:SEEL] has a current ratio of 0.10. On the other hand, the Quick Ratio is 0.10, and the Cash Ratio is 0.01. Considering the valuation of this stock, the price to sales ratio is 0.85 and price to earnings (TTM) ratio is 0.01.

Transactions by insiders

Recent insider trading involved Golembiewski Michael Joseph, Chief Financial Officer, that happened on Nov 30 ’23 when 83000.0 shares were purchased., Mehra Raj completed a deal on Dec 01 ’23 to buy 75757.0 shares.

Related Posts